Polynucleotide for inhibiting syn2a, exosome containing same, and use thereof

By loading polynucleotides and small nucleic acid molecules targeting the syn2a gene into exosomes, efficient treatment of post-traumatic stress disorder is achieved, and the safety and effectiveness of PTSD drugs in the prior art are solved, and the A novel low toxicity, low immunogenic treatment regimen.

WO2024239571A1PCT designated stage expired Publication Date: 2024-11-28SUZHOU EV MEDICAL CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/134677
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2023-11-28
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

There is a lack of safe and effective treatment of post-traumatic stress disorder (PTSD) in the prior art, traditional therapies such as exposure therapy are inefficient and psychological dependence and addictive problems for drugs such as SSRI drugs.

Method used

Polynucleotides and small nucleic acid molecules targeting the syn2a gene were designed to inhibit syn2a expression through siRNA sequence, load them into exosomes, and delivered to the target by intravenous injection, achieving efficient and tissue-specific delivery and expression. inhibition.

Benefits of technology

In the mouse model, the straightforwardness of fear memory is significantly reduced, effectively preventing and treating post-traumatic stress disorder, and the low immunogenicity and toxicity of exosome drugs avoid drug dependence and addiction risks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023134677_28112024_PF_FP_ABST
    Figure CN2023134677_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present application discloses a polynucleotide for inhibiting syn2a, an exosome containing same, and a use thereof. The present application provides a syn2a siRNA sequence, which can be used as a syn2a inhibitor for preventing / treating / assisting in treating post-traumatic stress disorder (PTSD). The present application further provides an exosome loaded with a syn2a siRNA sequence, and the exosome can efficiently deliver the syn2a siRNA sequence to a target gene in a tissue-specific manner, inhibit the expression of the target gene or an encoded protein of the target gene, have a significant treatment effect on fear memory refractory model mice, and can obviously reduce the average stiffness of the mice.
Need to check novelty before this filing date? Find Prior Art

Description

Polynucleotide for inhibiting syn2a, exosomes containing the same, and uses thereof

[0001] Cross-reference to related applications

[0002] This patent application claims priority to Chinese patent application No. 2023105755825, filed on May 22, 2023, entitled “Polynucleotides for inhibiting syn2a, exosomes containing the same and their uses”. The full text of the above application is incorporated herein by reference. Technical Field

[0003] The embodiments of the present invention relate to the field of biomedicine, and in particular to polynucleotides for inhibiting syn2a, exosomes containing the same, and uses thereof. Background Art

[0004] Post-traumatic stress disorder (PTSD) is a psychiatric disorder primarily triggered by intense trauma, and its symptoms can persist for months or even decades. Furthermore, PTSD often coexists with other psychiatric conditions, such as depression and suicidal thoughts. Therefore, the treatment of PTSD is even more urgent. However, the most commonly used clinical approach is currently exposure therapy, guided by a psychologist or psychiatrist. This process is ineffective and can require a long course of treatment to overcome the painful memories. Of course, there are currently some drug therapies, such as antidepressants like the SSRIs fluoxetine (Prozac) and paroxetine (Paxil), which are effective in treating some symptoms of PTSD. However, these drugs have the potential for psychological dependence and addiction. Therefore, the development of new and safe medications for the treatment of PTSD is crucial.

[0005] Summary of the Invention

[0006] The object of the present invention is to provide a polynucleotide for inhibiting syn2a.

[0007] Another object of the present invention is to provide exosomes.

[0008] Another object of the present invention is to provide a pharmaceutical composition.

[0009] Another object of the present invention is to provide a method for preventing, treating and / or assisting in the treatment of post-traumatic stress disorder.

[0010] In order to solve the above technical problems, the present invention provides an isolated polynucleotide in the first aspect, wherein the polynucleotide is selected from any one of the following:

[0011] (i) the polynucleotide shown in SEQ ID NO: 1;

[0012] (ii) a polynucleotide having a homology greater than 80% with the sequence shown in SEQ ID NO: 1; and (iii) a polynucleotide formed by substitution, deletion or addition of one or more nucleotides of the sequence shown in SEQ ID NO: 1.

[0013] The second aspect of the present invention provides a small nucleic acid molecule containing the polynucleotide described in the first aspect of the present invention, wherein the small nucleic acid molecule is siRNA, siRNA precursor, dsRNA, shRNA, miRNA or small interfering RNA.

[0014] The third aspect of the present invention provides an exosome containing the polynucleotide described in the first aspect of the present invention or the small nucleic acid molecule described in the second aspect of the present invention.

[0015] The fourth aspect of the present invention provides a pharmaceutical composition comprising: the polynucleotide described in the first aspect of the present invention / the small nucleic acid molecule described in the second aspect of the present invention / the exosomes described in the third aspect of the present invention, and a pharmaceutically acceptable carrier.

[0016] In a fifth aspect, the present invention provides a method for preventing, treating and / or assisting in the treatment of post-traumatic stress disorder, comprising the steps of administering to a subject a therapeutically effective amount of the polynucleotide of the first aspect of the present invention, or administering to a subject a therapeutically effective amount of the small nucleic acid molecule of the second aspect of the present invention, or administering to a subject a therapeutically effective amount of the exosomes of the third aspect of the present invention, or administering to a subject a therapeutically effective amount of the pharmaceutical composition of the fourth aspect of the present invention.

[0017] In some preferred embodiments, the administration is by intravenous injection.

[0018] The sixth aspect of the present invention provides the use of the polynucleotide according to the first aspect of the present invention for:

[0019] (i) prevention, treatment and / or auxiliary treatment of post-traumatic stress disorder;

[0020] (ii) preparing a medicament for preventing, treating and / or assisting in the treatment of post-traumatic stress disorder;

[0021] (iii) non-therapeutic reduction of the expression level of the syn2a gene or its encoded protein in vitro; and / or

[0022] (iv) Acts as a syn2a inhibitor.

[0023] The seventh aspect of the present invention provides the use of the small nucleic acid molecule according to the second aspect of the present invention for:

[0024] (i) prevention, treatment and / or auxiliary treatment of post-traumatic stress disorder;

[0025] (ii) preparing a medicament for preventing, treating and / or assisting in the treatment of post-traumatic stress disorder;

[0026] (iii) non-therapeutic reduction of the expression level of the syn2a gene or its encoded protein in vitro; and / or

[0027] (iv) Acts as a syn2a inhibitor.

[0028] In an eighth aspect, the present invention provides a use of the exosomes according to the third aspect of the present invention for:

[0029] (i) prevention, treatment and / or auxiliary treatment of post-traumatic stress disorder;

[0030] (ii) preparing a medicament for preventing, treating and / or assisting in the treatment of post-traumatic stress disorder;

[0031] (iii) non-therapeutic reduction of the expression level of the syn2a gene or its encoded protein in vitro; and / or

[0032] (iv) Acts as a syn2a inhibitor.

[0033] A ninth aspect of the present invention provides a method for preparing exosomes containing the polynucleotide according to the first aspect of the present invention, the method comprising the steps of:

[0034] Original exosomes are obtained, and then the polynucleotides described in the first aspect of the present invention are introduced into the original exosomes to obtain exosomes containing the polynucleotides described in the third aspect of the present invention.

[0035] In some preferred embodiments, the polynucleotide described in the first aspect of the present invention is introduced into the original exosomes by electrotransduction or chemical transduction.

[0036] In some preferred embodiments, the raw exosomes are obtained by treating cells with an ECS reagent.

[0037] Compared with the prior art, the present invention has at least the following advantages:

[0038] (1) The present invention provides a syn2a siRNA sequence, which can be used as a syn2a inhibitor for the prevention / treatment / adjuvant treatment of post-traumatic stress disorder (PTSD);

[0039] (2) The present invention also provides an exosome loaded with a syn2a siRNA sequence, which can efficiently and tissue-specifically deliver the syn2a siRNA sequence to the target gene, inhibiting the expression of the target gene or its encoded protein. In a mouse animal model, tail vein injection of the exosome-encapsulated syn2a siRNA can significantly reduce the average rigidity rate of ordinary C57 mice and mice with a fear memory refractory model. Therefore, the exosome drug is therapeutic and can effectively prevent and / or treat and / or assist in the treatment of PTSD.

[0040] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] One or more embodiments are exemplarily described by the figures in the corresponding drawings, and these exemplified descriptions do not constitute limitations on the embodiments.

[0042] FIG1 shows the metabolic status of DiD-labeled exosomes in vivo after injection of DiD dye into the tail vein of mice according to an embodiment of the present invention, at 0, 2, and 8 hours.

[0043] Figure 2 is a comparison of Western blot results of syn2a / b proteins in the cerebral cortex after tail vein injection of control exosomes and si-syn2a exosomes in mice according to an embodiment of the present invention, wherein Con is the control group, Si-syn2a is the experimental group, GAPDH is the internal reference, and t-test analysis was used. Data are mean ± standard error, **P < 0.01;

[0044] Figure 3 shows the changes in freezing rate in the control group and the si-syn2a exosome group during the extinction of fear memory after tail vein injection of control RNA exosomes and si-syn2a exosomes in ordinary C57BL / 6J mice according to an embodiment of the present invention. Data are mean ± standard error, *P < 0.05;

[0045] Figure 4 is a t-test analysis of the control group and the si-syn2a exosome group after tail vein injection of control RNA exosomes and si-syn2a exosomes in ordinary C57BL / 6J mice according to an embodiment of the present invention. There was no significant difference in the freezing rate between the control group and the si-syn2a exosome group during the fear memory acquisition stage, but there was a significant change in the freezing rate during the fear memory extinction test (n=5). Data are mean ± standard error, *P<0.05.

[0046] FIG5 is a two-way ANOVA analysis of the changes in freezing rate in the control group and the si-syn2a exosome group during the extinction of fear memory after tail vein injection of control RNA exosomes and si-syn2a exosomes in AtLAS- / - mice according to an embodiment of the present invention;

[0047] Figure 6 shows a t-test analysis of the freezing rates of the control group and the si-syn2a exosome group in the fear memory acquisition phase according to an embodiment of the present invention. There was no significant difference in the freezing rate, but there was a significant change in the freezing rate in the fear memory extinction test (n=7). Data are mean ± standard error, *P<0.05, **P<0.01. DETAILED DESCRIPTION

[0048] Currently, there are no safer, effective treatments for PTSD. RNA interference (RNAi), a new gene therapy technology, has broad application prospects in antiviral, anti-tumor, and anti-inflammatory medicine and has rapidly developed. Some RNA drugs have entered clinical trials, opening up new treatment avenues for difficult and complex diseases, especially multifactorial diseases such as cancer and viral infections. However, small interfering RNA must be intracellular to function. RNA molecules are negatively charged and sensitive to nucleases widely present in the body, making them difficult to deliver to target genes for therapeutic effects.

[0049] After extensive and in-depth research, the inventors have designed a nucleic acid drug that targets the syn2a gene and inhibits its expression. In addition, the inventors have found that when loaded into exosomes, it has low immunogenicity, low toxicity, and no induced mutations in vivo, and is excellent for delivering small interfering RNA to treat post-traumatic stress disorder. Therefore, the use of exosomes containing the polynucleotide of the present invention as a drug for treating PTSD is a very novel, feasible and effective method.

[0050] polynucleotides

[0051] The present invention relates to an isolated polynucleotide for inhibiting the expression of syn2a and its encoded protein. As a nucleic acid drug, it can bind to the target gene syn2a to inhibit syn2a expression. As used in the present invention, the term "polynucleotide" or "nucleic acid" refers to a nucleotide or nucleotide monomer sequence composed of naturally occurring bases, sugars and sugar (hubs). The term also includes a limited or replaced sequence containing a monomer or a portion thereof that does not exist in nature. The polynucleotide sequence of the present invention can be a deoxyribonucleic acid sequence (DNA) or a ribonucleic acid sequence (RNA), and can contain natural bases of adenine, guanine, cytosine and uracil. In one embodiment of the present invention, the polynucleotide is a polynucleotide whose ribonucleic acid sequence is as shown in SEQ ID NO: 1. In one embodiment of the present invention, the polynucleotide is a polynucleotide whose ribonucleic acid sequence is greater than 80% (preferably greater than 90%, further preferably greater than 95%, further preferably greater than 98%, and even more preferably greater than 99%) compared to the sequence shown in SEQ ID NO: 1. In one embodiment of the present invention, the polynucleotide comprises a ribonucleic acid sequence derived from the sequence shown in SEQ ID NO:1, with one or more nucleotides substituted, deleted, or added. The inventors designed multiple polynucleotides targeting the target gene syn2a. After screening and validation, the aforementioned polynucleotide sequence was identified, which exhibited the strongest ability to inhibit syn2a expression at the same dose. The aforementioned SEQ ID NO:1 is: CCCAGAAATGACCATGTGATA.

[0052] As used in the present invention, the terms "homology", "sequence identity" and "percentage of identity" are used interchangeably and refer to the percentage of identical (i.e., identical) nucleotides or amino acids between two or more polynucleotides or polypeptides. The sequence identity between two or more polynucleotides or polypeptides can be measured by the following method. The nucleotide or amino acid sequences of the polynucleotides or polypeptides are arranged, and the number of positions containing the same nucleotide or amino acid residue in the arranged polynucleotides or polypeptides is scored and compared with the number of positions containing different nucleotides or amino acid residues in the arranged polynucleotides or polypeptides. The polynucleotides can differ at one position, for example, by comprising different nucleotides (i.e., substitutions or variations) or deletions of nucleotides (i.e., insertions or deletions of one or two nucleotides in the polynucleotides). The polypeptides can differ at one position, for example, by containing an amino acid (i.e., substitutions or variations) or a deletion of an amino acid (i.e., insertions of an amino acid or deletion of an amino acid in one or two polypeptides). Sequence identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residue by the total number of amino acid residues in the polynucleotides or polypeptides. For example, percent identity can be calculated by dividing the number of positions containing the identical nucleotide or amino acid residue by the total number of nucleotides or amino acid residues in the polynucleotide or polypeptide and multiplying by 100.

[0053] small nucleic acid molecules

[0054] The present invention also relates to a small nucleic acid molecule containing the above polynucleotide, and the small nucleic acid molecule can be at least one of siRNA, siRNA precursor, dsRNA, shRNA, miRNA or small interfering RNA.

[0055] As used herein, the term "RNAi" (RNA interference) refers to a phenomenon that is highly conserved in the evolutionary process, induced by double-stranded RNA (dsRNA), and efficiently and specifically degrades RNA with a complementary paired sequence. Since the use of RNAi technology can specifically shut down the expression of specific genes, this technology has been widely used in fields such as exploring gene function and gene therapy for infectious diseases and tumors. The dsRNA-mediated RNAi phenomenon has been found in a variety of eukaryotic organisms such as fungi, fruit flies, Arabidopsis, trypanosomes, hydra, planarians, zebrafish, etc., and posttranscriptional gene silencing (PTGS), cosuppression, and RNA-mediated virus resistance and fungal inhibition (quelling) in plants are also manifestations of RNAi in different species.

[0056] As used herein, the term "siRNA" (Small interfering RNA, siRNA) refers to a small RNA molecule (approximately 21-25 nucleotides) that can be processed by Dicer (an enzyme in the RNase III family that is specific for double-stranded RNA) from precursors (such as dsRNA, shRNA, etc.). It can also be chemically synthesized or produced by processing other proteins. siRNA is a key member of the siRISC (siRISC) complex, stimulating the rapid cleavage and degradation of target RNAs with complementary sequences, leading to silencing of the target gene, making it a key functional molecule in RNAi. Given a specific gene target sequence, those skilled in the art can design and obtain siRNAs specific to that target sequence using conventional methods.

[0057] As used herein, the term "siRNA precursor" refers to an RNA molecule that can be processed in mammalian cells to produce siRNA, specifically, it is selectively processed by Dicer or other similar proteins to produce mature siRNA, thereby implementing RNAi.

[0058] As used herein, the term "miRNA" (microRNA) refers to a class of non-coding, single-stranded RNA molecules approximately 20-24 nucleotides in length, encoded by endogenous genes. They are involved in regulating the expression of numerous genes in plants and animals. To date, over 4,000 miRNA molecules have been discovered in plants, animals, and viruses. Most miRNA genes exist in the genome as single copies, multiple copies, or clusters. Each miRNA can regulate multiple target genes, and several miRNAs can also jointly regulate the same gene, forming a complex regulatory network. It is speculated that miRNAs regulate the expression of more than half of all human genes. MiRNAs exist in various forms, the most primitive of which is pri-miRNA. Pri-miRNAs are processed by Drosha to become pre-miRNAs, or miRNA precursors, approximately 50-90 nucleotides in length. Pre-miRNAs are then cleaved by the enzyme Dicer to become mature miRNAs of approximately 20-24 nucleotides in length. MiRNAs inhibit target gene expression primarily by inhibiting translation and accelerating mRNA deadenylation, a mechanism distinct from siRNA-mediated mRNA degradation.

[0059] One way to produce small interfering RNA (siRNA) in vivo is to clone the siRNA sequence as part of a "short hairpin" into a plasmid vector. When delivered into an animal, the hairpin sequence is expressed to form a double-stranded RNA (shRNA) with a top loop structure, which is recognized and processed by the Dicer protein in the cell to produce functional siRNA.

[0060] As used herein, the terms "shRNA" and "shRNA" are used interchangeably and refer to a special type of shRNA constructed using the precursor of human miR-26b as a backbone. The shRNA comprises, from the 5' end to the 3' end, the following: (a) a 5' flanking sequence region; (b) a 5' pairing siRNA region; (c) an apical loop region; (d) a 3' pairing siRNA region, wherein the 5' pairing siRNA region and the 3' pairing siRNA region form a double-stranded region; and (e) a 3' flanking sequence region. The shRNA produces an siRNA, and the nucleotide sequence of the siRNA corresponds to the 3' pairing siRNA region or the 5' pairing siRNA region.

[0061] In a broad sense, shRNA stands for short hairpin RNA. shRNA consists of two short reverse-complementary sequences separated by a loop sequence, forming a hairpin structure. Transcription is typically controlled by an endogenous RNA polymerase III promoter. Five to six Ts are attached to the end of the shRNA sequence, acting as a transcriptional terminator for RNA polymerase III. shRNA can also be transcribed from promoters of other RNA polymerases.

[0062] exosomes

[0063] The present invention also relates to exosomes containing the aforementioned polynucleotides. As used herein, the terms "exosome" and "exosome" are used interchangeably and refer to vesicles produced by cells with a diameter of 30 to 100 nm and a lipid bilayer membrane structure. Exosomes are secreted by living cells and naturally occur in body fluids, including blood, saliva, urine, cerebrospinal fluid, and breast milk. They are released from cells by fusion of late endosomes with the cell membrane or directly through the cell membrane, playing an important role in intercellular signaling. In one embodiment of the present invention, the exosomes contain the polynucleotide set forth in SEQ ID NO: 1. In one embodiment of the present invention, the exosomes contain a polynucleotide having greater than 80% (preferably greater than 90%, more preferably greater than 95%, more preferably greater than 98%, and even more preferably greater than 99%) homology to the sequence set forth in SEQ ID NO: 1. In one embodiment of the present invention, the exosomes contain a polynucleotide formed by substitution, deletion, or addition of one or more nucleotides to the sequence set forth in SEQ ID NO: 1.

[0064] In a preferred embodiment, the exosomes may be further engineered, such as targeted modification or loading modification. In one embodiment of the present invention, the purified exosomes are subjected to loading modification, and the polynucleotide of the present invention is exogenously loaded (post-modification).

[0065] Method for preparing exosomes

[0066] The present invention also relates to a method for preparing exosomes containing polynucleotides, comprising the steps of:

[0067] (1) Obtaining raw exosomes;

[0068] (2) The polynucleotide is introduced into the original exosomes to obtain exosomes containing the polynucleotide.

[0069] In the present invention, raw exosomes refer to exosomes obtained directly from cells without being loaded with exogenous target sequences. Raw exosomes can be obtained by conventional methods in the art, such as using a commercially available exosome extraction kit and following the kit instructions. In a preferred embodiment of the present invention, raw exosomes are obtained by treating cells with ECS (Exosomoe Concentration Solution) reagent.

[0070] The polynucleotides of the present invention can be introduced into exosomes using conventional nucleic acid delivery methods in the art, that is, the target polynucleotide sequence is engineered and loaded into the exosomes. Depending on whether the loading operation occurs before the exosome purification step or after the exosome purification step, the loading is divided into exogenous loading or endogenous loading. Exogenous loading is to first purify the obtained exosomes, and then introduce the target polynucleotides into the purified exosomes by electrotransduction methods such as electroporation or chemical transduction. Endogenous loading is to first transform the source cells, for example, by directly transfecting or co-incubating the target polynucleotides into the source cells, and then causing the source cells to produce exosomes to obtain exosomes containing the target polynucleotides. In a preferred embodiment of the present invention, the target polynucleotides are introduced into exosomes using an exogenous loading method to obtain exosomes containing the target polynucleotides.

[0071] The method for purifying exosomes is carried out according to conventional methods in the art. For example, the crude exosome particles are purified using an Exosomoe Purification Filter (EPF column), centrifuged at 3000g for 10 min at 4°C, and the liquid at the bottom of the EPF column is collected after centrifugation to obtain purified exosome particles.

[0072] Pharmaceutical composition

[0073] The present invention also relates to a pharmaceutical composition comprising the polynucleotide of the present invention or the exosome of the present invention, and a pharmaceutically acceptable carrier.

[0074] As used in the present invention, the term "pharmaceutically acceptable carrier" may include one or more of a pharmaceutically acceptable excipient, a buffer, a stabilizer, or other substances known to those skilled in the art. Examples of pharmaceutically acceptable carriers include, but are not limited to, one or more of water, saline, a buffer, an isotonic agent such as a sugar, a polyol, an auxiliary substance such as a wetting agent or an emulsifier, a preservative, and a combination thereof. Such materials should be nontoxic and should not interfere with the efficacy of the active ingredient at the dosage and concentration employed. The exact nature of the carrier or other substance may depend on the route of administration, such as intramuscular, subcutaneous, oral, intravenous, skin, mucosal (e.g., intestinal), intranasal, or intraperitoneal. In some embodiments of the present invention, the pharmaceutical composition comprises a polynucleotide of the present invention and a nucleic acid delivery vehicle as a pharmaceutically acceptable carrier, examples of which include liposomes, biocompatible polymers (including natural polymers and synthetic polymers), lipoproteins, polypeptides, polysaccharides, lipopolysaccharides, artificial viral envelopes, metal particles, and bacteria, viruses (such as baculoviruses, adenoviruses and retroviruses), phages, cosmids, plasmids, fungal vectors, and other recombinant vectors commonly used in the art and described as being expressed in various eukaryotic hosts.

[0075] Treatment

[0076] The present invention also relates to a method for preventing, treating and / or assisting in the treatment of post-traumatic stress disorder, comprising the steps of administering a therapeutically effective amount of the above-mentioned polynucleotide to a subject, or administering a therapeutically effective amount of exosomes to a subject, or administering a therapeutically effective amount of a pharmaceutical composition to a subject.

[0077] As used herein, the term "treating" refers to eradicating or ameliorating a disease or condition, or one or more symptoms associated with the disease or condition. In one embodiment, such symptoms are known to those skilled in the art to be associated with the disease or condition to be treated. In specific embodiments, the term refers to minimizing the spread or worsening of the disease or condition by administering one or more preventive or therapeutic agents to a subject suffering from the disease or condition. In some embodiments, the term refers to administering a compound of the invention, with or without other additional active agents, after the onset of symptoms of a particular disease.

[0078] As used herein, the term "prevention" refers to preventing the onset, recurrence, or spread of a disease or condition, or one or more symptoms associated with the disease or condition. In one embodiment, the symptom is known to those skilled in the art to be associated with the disease or condition to be prevented. In a specific embodiment, the term refers to administering the polynucleotides or exosomes of the present invention, with or without other additional active agents, to a patient at risk for a disease or disorder described herein prior to the onset of symptoms. The term encompasses both the suppression and reduction of symptoms of a particular disease. In a specific embodiment, patients with a family history of a disease are specifically considered candidates. In addition, patients with a history of recurring symptoms are also potential candidates for prevention. In this regard, the term "prevention" is used interchangeably with the term "prophylactic treatment."

[0079] As used herein, a "therapeutically effective amount" of a polynucleotide or exosome refers to an amount of the agent sufficient to provide a therapeutic effect in the treatment or management of a disease or disorder, or sufficient to delay or minimize one or more symptoms associated with the disease or disorder. A therapeutically effective amount of a compound refers to an amount of a therapeutic agent that, when used alone or in combination with other therapies, provides a therapeutic effect in the treatment or management of a disease or disorder. The term "therapeutically effective amount" may include an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or disorder, or enhances the therapeutic efficacy of another therapeutic agent.

[0080] As used herein, the term "subject" is defined herein to include animals, such as mammals, including but not limited to primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc. In certain embodiments, the subject is a human.

[0081] As a mode of administration of the polynucleotide, exosome or pharmaceutical composition of the present invention, oral, parenteral, inhalation spray, topical, rectal, nasal, oral, vaginal or via an implanted reservoir can be selected. As used herein, the term "parenteral" includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intraperitoneally or intravenously. In a more preferred embodiment of the present invention, the mode of administration is intravenous injection.

[0082] use

[0083] The present invention also relates to the use of the above-mentioned polynucleotide, exosome or pharmaceutical composition for

[0084] (i) prevention, treatment and / or auxiliary treatment of post-traumatic stress disorder;

[0085] (ii) preparing a medicament for preventing, treating and / or assisting in the treatment of post-traumatic stress disorder;

[0086] (iii) non-therapeutic reduction of the expression level of the syn2a gene or its encoded protein in vitro; and / or

[0087] (iv) Acts as a syn2a inhibitor.

[0088] As used in the present invention, the term "and / or" should be considered as a specific disclosure of each of the two specified features or components, with or without the other. Therefore, the term "and / or" used in phrases such as "A and / or B" herein is intended to include "A and B", "A or B", "A" (alone) and "B" (alone). Similarly, the term "and / or" used in the term "A, B and / or C" is intended to cover the following aspects: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0089] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and parts by weight. The experimental materials and reagents used in the following examples can be obtained from commercial sources unless otherwise specified.

[0090] Unless otherwise specified, the technical and scientific terms used herein have the same meaning as commonly understood by ordinary technicians in the technical field to which this application belongs. It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments of this application.

[0091] Example 1

[0092] In this example, exosomes were extracted and purified. The specific steps are as follows:

[0093] For routine mouse cell culture, the supernatant was first pretreated. Exosomoe Concentration Solution (ECS reagent) was added to the centrifuged supernatant after impurities were removed. After adding the ECS reagent, the centrifuge tube was tightly capped, mixed by vortexing for 1 minute, and then placed at 4°C for 2 hours; the centrifuge tube containing the mixture was removed and centrifuged at 10,000g for 60 minutes at 4°C, and the supernatant was discarded. The precipitate was rich in exosome particles; 100 μL of 1× PBS was taken and evenly blown on the centrifuged precipitate. After it was evenly suspended in PBS, the resuspension was transferred to a new 1.5 mL centrifuge tube; the 1.5 mL centrifuge tube containing the resuspension was centrifuged at 12,000g for 2 minutes at 4°C, and the supernatant was retained. The supernatant was rich in exosome particles.

[0094] The harvested crude exosome particles were transferred to the upper chamber of the Exosomoe Purification Filter (EPF column) and centrifuged at 3000 g for 10 min at 4°C. After centrifugation, the liquid at the bottom of the EPF column was collected. This liquid was the purified exosome particles.

[0095] Example 2

[0096] In this example, in order to better determine the localization of our exosomes, the purified exosomes obtained in Example 1 were labeled with fluorescent dyes. The specific steps are as follows:

[0097] Preparation of dye working solution: dilute the stock solution with Diluent C to prepare a 100 μM dye working solution (protect from light).

[0098] Exosome staining: Add dye working solution to the exosomes. After adding the dye working solution, tightly cap the centrifuge tube and mix by vortexing for 1 minute. Then incubate for 10 minutes. Add 1 mL of 1X PBS to the incubated exosome-dye complex and mix thoroughly. Extract the exosomes again according to the exosome extraction method to remove excess dye. Resuspend the precipitate in 100 μL of 1× PBS. The precipitate is the labeled exosomes.

[0099] Example 3

[0100] In this example, siRNA was electroporated into exosomes labeled with fluorescent dyes. The specific steps are as follows:

[0101] The fluorescent dye-labeled exosomes obtained in Example 2 were taken and 100 μg of si-syn2a was electroporated into the exosomes using an electroporation procedure.

[0102] The fluorescent dye-labeled exosomes obtained in Example 2 were electroporated sequentially into the exosomes with 100 μg of other siRNA sequences designed by the inventors to obtain a control group. For example, the siRNA NC sequence was electroporated into the exosomes to obtain a control group.

[0103] syn2a siRNA (SEQ ID NO:1):CCCAGAAATGACCATGTGATA;

[0104] siRNA NC sequence (SEQ ID NO:2): TTCTCCGAACGTGTCACGT.

[0105] Example 4

[0106] In this example, exosomes were injected into the brains of experimental animals to conduct behavioral experiments on the extinction of cued conditioned fear memory.

[0107] The exosomes obtained in Example 3 were injected into mice via tail vein injection. The distribution of the exosomes in the body was observed using small animal in vivo imaging technology at 0 hours, 2 hours, and 8 hours (Figure 1). The inventors found that the exosomes had entered the brain at 2 hours and could maintain this effect for up to 8 hours.

[0108] The inventors tested the effect of si-syn2a exosome drugs through classic cue-conditioned fear memory extinction behavior. First, 10 male 8-10 week old wild-type mice were selected. Before the start of the experiment, exosomes were injected into the tail vein 6 hours in advance (5 experimental groups and 5 control groups). On the first day of the experiment, the mice were placed in an electric shock box. At this time, the electric shock box scene was A and the odor was low-concentration ethanol. After 3 minutes, the first foot shock (0.8mA, 1s) was paired with a sound (80dB, 4000hz, 30s). That is, a 1s electric shock was given 29s after the sound appeared, and the sound and shock ended at the same time. After 5 such pairing exercises, with an interval of 20s, the mice were taken out and returned to the cage 60s after the last training, and the freezing rate of each mouse was recorded. The next day, the mice underwent fear memory conditioning. On the third day of the experiment, exosomes were injected into the tail vein 6 hours before fear extinction training. Mice were placed in an experimental chamber, and the chamber environment was changed to Scenario B, where the odor was low-concentration acetic acid. After acclimation for 3 minutes, a 14-cycle sound stimulus (80 dB, 4000 Hz, 20 s) was presented, without electric shock, with a 20 s interval between each sound stimulus. 60 s after the last training session, the mice were removed from the experimental chamber and returned to their cages, and the freezing rate was recorded. On the fourth day of the experiment, the same procedures were followed as on the third day, and the freezing rate was finally calculated. The experiment achieved the expected results. The freezing rate was significantly reduced in the group receiving si-syn2a exosomes (Figures 3-4). Simultaneously, the mice were killed and brain tissue was obtained. Western blotting confirmed that the si-syn2a exosome-treated group had reduced syn2a protein levels in the brain compared to the control group (Figure 2).

[0109] At the same time, referring to existing methods, we developed an AtLAS- / - mouse model, a model of refractory fear memory extinction. This model is a well-established PTSD model. The same behavioral experiments were used to validate this approach. Statistical analysis revealed that the freezing rate in AtLAS- / - mice injected with si-syn2a exosomes was significantly lower than that in AtLAS- / - mice injected with control exosomes (Figures 5-6).

[0110] Those skilled in the art will appreciate that the above-mentioned embodiments are specific examples for implementing the present invention, and that in actual applications, various changes may be made thereto in form and detail without departing from the spirit and scope of the present invention.

Claims

1. An isolated polynucleotide, characterized in that The polynucleotide is used as a syn2a inhibitor, and the polynucleotide is selected from any one of the following: (i) a polynucleotide as shown in SEQ ID NO: 1; (ii) a polynucleotide having a homology greater than 80% with the sequence shown in SEQ ID NO: 1; and (iii) A polynucleotide formed by substitution, deletion or addition of one or more nucleotides in the sequence shown in SEQ ID NO:

1.

2. A small nucleic acid molecule comprising the polynucleotide according to claim 1, wherein the small nucleic acid molecule is siRNA, siRNA precursor, dsRNA, shRNA, miRNA or small interfering RNA.

3. An exosome containing the polynucleotide according to claim 1 or the small nucleic acid molecule according to claim 2.

4. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises: the polynucleotide according to claim 1 or the small nucleic acid molecule according to claim 2, and a pharmaceutically acceptable carrier.

5. A method for preventing, treating and / or assisting in the treatment of post-traumatic stress disorder, characterized in that: The method comprises the steps of: applying a therapeutically effective amount of the polynucleotide of claim 1 to a subject; or Applying a therapeutically effective amount of the small nucleic acid molecule of claim 2 to a subject; or Applying a therapeutically effective amount of the exosomes according to claim 3 to a subject; or A therapeutically effective amount of the pharmaceutical composition of claim 4 is administered to the subject.

6. Use of the polynucleotide according to claim 1, for: (i) prevention, treatment and / or auxiliary treatment of post-traumatic stress disorder; (ii) preparing a medicament for preventing, treating and / or assisting in the treatment of post-traumatic stress disorder; (iii) non-therapeutically reducing the expression level of the syn2a gene or its encoded protein in vitro; and / or (iv) Use as a syn2a inhibitor.

7. Use of the small nucleic acid molecule according to claim 2, for: (i) prevention, treatment and / or auxiliary treatment of post-traumatic stress disorder; (ii) preparing a medicament for preventing, treating and / or assisting in the treatment of post-traumatic stress disorder; (iii) non-therapeutically reducing the expression level of the syn2a gene or its encoded protein in vitro; and / or (iv) Use as a syn2a inhibitor.

8. The use of the exosomes according to claim 3, for: (i) prevention, treatment and / or auxiliary treatment of post-traumatic stress disorder; (ii) preparing a medicament for preventing, treating and / or assisting in the treatment of post-traumatic stress disorder; (iii) non-therapeutically reducing the expression level of the syn2a gene or its encoded protein in vitro; and / or (iv) Use as a syn2a inhibitor.

9. The method for preparing exosomes according to claim 3, characterized in that: The method comprises the steps of: The original exosomes are obtained, and then the polynucleotide according to claim 1 is introduced into the original exosomes.

10. The method according to claim 8, characterized in that The raw exosomes are obtained by treating cells with an ECS reagent.

Citation Information

Patent Citations

  • Application of adenosine compound in preparation of drugs for prevention and treatment of stress disorders

    CN104173363A

  • Application of small dose of propofol in preparing products for preventing and curing post-traumatic stress disorder (PTSD)

    CN106109449A

  • Method for evaluating neurodevelopment toxicity of perfluorinated compounds by utilizing zebra fishes

    CN109633140A

  • Polynucleotide for inhibiting syn2a, exosome containing same and use thereof

    CN116814620A